Analyst Price Targets — ATRC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 2, 2026 11:13 am | Mike Matson | Needham | $64.00 | $48.92 | StreetInsider | AtriCure Inc. (ATRC) PT Raised to $64 at Needham |
| August 27, 2026 10:48 am | Matt O'Brien | Piper Sandler | $60.00 | $48.17 | TheFly | AtriCure price target raised to $60 from $50 at Piper Sandler |
| August 24, 2026 10:26 am | Marie Thibault | BTIG | $55.00 | $48.98 | StreetInsider | AtriCure Inc. (ATRC) PT Raised to $55 at BTIG |
| July 28, 2026 12:20 pm | — | UBS | $50.00 | $38.47 | TheFly | AtriCure price target lowered to $50 from $55 at UBS |
| July 21, 2026 8:47 am | — | Raymond James | $52.00 | $34.77 | StreetInsider | AtriCure (ATRC) Reiterated at Market Outperform by Citizens on Consistent Product Iteration |
| May 6, 2026 12:33 pm | — | Canaccord Genuity | $55.00 | $28.60 | TheFly | AtriCure price target raised to $55 from $53 at Canaccord |
| February 18, 2026 12:08 pm | — | UBS | $55.00 | $32.97 | TheFly | AtriCure price target lowered to $55 from $60 at UBS |
| February 18, 2026 12:02 pm | William Plovanic | Canaccord Genuity | $53.00 | $32.97 | TheFly | AtriCure price target lowered to $53 from $64 at Canaccord |
| February 18, 2026 11:09 am | — | Oppenheimer | $44.00 | $32.97 | TheFly | AtriCure downgraded to Perform from Outperform at Oppenheimer |
| October 30, 2025 10:27 am | William Plovanic | Canaccord Genuity | $64.00 | $35.44 | StreetInsider | AtriCure Inc. (ATRC) PT Raised to $64 at Canaccord Genuity |
Latest News for ATRC
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday,…
AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.
AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.
On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ATRC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.